Ondansetron 4 mg ODT Prescribing Instructions
For ondansetron 4 mg orally disintegrating tablets, write: "Take one tablet by mouth 30 minutes before chemotherapy, then every 8-12 hours as needed for nausea" and dispense 30 tablets for a standard chemotherapy cycle.
Sig (Directions for Use)
The specific sig depends on the clinical indication:
For Chemotherapy-Induced Nausea/Vomiting
- "Take 2 tablets (8 mg) by mouth 30 minutes before chemotherapy, then 2 tablets every 8 hours for 1-2 days after chemotherapy" 1
- This provides the FDA-approved dosing of 8 mg administered 30 minutes pre-chemotherapy with subsequent 8-hour dosing
- For moderately emetogenic chemotherapy, twice-daily dosing (every 12 hours) is equally effective and may improve compliance 1
For Radiation-Induced Nausea/Vomiting
- "Take 2 tablets (8 mg) by mouth 1-2 hours before radiation therapy, then every 8 hours on radiation days" 2, 1
- The ASCO guideline specifies 8 mg dosing for moderate to high-risk radiation therapy 2
For Postoperative Nausea/Vomiting
- "Take 4 tablets (16 mg) by mouth 1 hour before surgery" 1
- This is a single-dose regimen
For Pediatric Gastroenteritis (Off-label)
- "Take 1 tablet (4 mg) by mouth once for children 8-15 kg; take 2 tablets (8 mg) for children >15 kg"
- Dosing range of 0.13-0.26 mg/kg shows equivalent efficacy 3
Quantity to Dispense
Standard dispensing quantities:
Chemotherapy cycles: 30-60 tablets
- Covers 3-5 days of treatment at 8 mg three times daily (6 tablets/day = 18-30 tablets per cycle)
- Add buffer for breakthrough nausea: dispense 30 tablets minimum 1
Radiation therapy: 60-90 tablets
Postoperative use: 4 tablets
- Single 16 mg dose (4 tablets) 1
Breakthrough/PRN use: 15-30 tablets
- For rescue therapy as needed
Key Prescribing Considerations
Formulation advantages: The orally disintegrating tablet disperses rapidly on the tongue without water, making it ideal for patients with dysphagia or active nausea who cannot swallow conventional tablets 5, 4. The ODT formulation is bioequivalent to conventional tablets and equally effective 5.
Dosing pitfalls to avoid:
- Do not prescribe 8 mg three times daily for moderately emetogenic chemotherapy—this is NOT recommended by FDA 1
- Twice-daily dosing (every 12 hours) is equally effective and preferred for compliance 1
- Maximum daily dose should not routinely exceed 24 mg due to QT prolongation risk 1
Cost considerations: ODT formulations are significantly more cost-effective than IV formulations while maintaining equivalent efficacy (approximately 50% cost reduction) 6
Storage instructions: Include on prescription: "Store at room temperature 68-77°F" 1